Bastiano Sanna, EVP, Cell & Genetic Therapies at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 8,764 shares at $350.32 ($3.1M) on 2023-05-02, disclosed to the SEC on 2023-05-04.
Scheduled sale ($3.1M) by EVP, Cell & Genetic Therapies under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $350.32 | 1,411 | $494K | 16.1% |
| 2 | $350.32 | 1,411 | $494K | 16.1% |
| 3 | $351.65 | 42 | $15K | 0.5% |
| 4 | $353.24 | 169 | $60K | 1.9% |
| 5 | $353.24 | 169 | $60K | 1.9% |
| 6 | $350.44 | 2,053 |
| $719K |
| 23.4% |
| 7 | $350.44 | 2,053 | $719K | 23.4% |
| 8 | $351.60 | 728 | $256K | 8.3% |
| 9 | $351.60 | 728 | $256K | 8.3% |
| Total | $350.71 avg | 8,764 | $3.1M | 100% |
| Filing → |
| VRTX | SELL | 2023-04-06 | $231K | — | Filing → |
| VRTX | SELL | 2023-03-20 | $1.7M | — | Filing → |
| VRTX | SELL | 2023-02-16 | $1.3M | — | Filing → |